Deep Blue receives Angel Capital Association award for life sciences innovation

Durham-based Deep Blue Medical Advances has been honored with the Angel Capital Association (ACA) 2024 Luis Villalobos Award in the life sciences category. 

The prestigious award signifies the most ingenious and innovative ideas recently backed by members of the ACA, a professional association of more than 15,000 accredited angel investors and 250 angel groups, accredited platforms and family offices across North America.

Deep Blue LogoTwo Luis Villalobos Awards are presented each year, with one technology category winner and one life sciences winner. The awards honor Luis Villalobos, founder of Tech Coast Angels, one of the largest and most respected angel organizations in the world.

The 2024 life sciences award recognizes Deep Blue’s work to transform soft tissue surgery by developing next-generation surgical devices to prevent soft tissue surgery failure. These include the T-Line Hernia Mesh and additional hernia and surgical products in development.

Bill Perry
Deep Blue CEO Bill Perry

Bill Perry, CEO of Deep Blue, accepted the award during a ceremony at the 2024 ACA Summit in Columbus, Ohio, on May 13. “We are honored to have received this prestigious award and grateful to our supporters,” said Perry. “If we are reaching new heights, it is because we are lifted up by our clinicians and investor partners, the lifeblood of the company.”

Howard Levinson
Deep Blue founder
Howard Levinson

Howie Levinson, founder of Deep Blue, also attended the event. “As a surgeon, I can help one patient at a time,” he said. “But as an inventor, I am deeply gratified to witness how an innovative platform can be developed and leveraged to help many more patients find relief and healing.”

The North Carolina Biotechnology Center has supported Deep Blue and its technology through a 2016 Technology Enhancement Grant to develop the hernia mesh technology and subsequent loans that helped the company secure FDA marketing clearance for T-Line. 

“We are delighted to see Deep Blue’s innovative work being acknowledged with this esteemed award,” said Greta Brunet, NCBiotech's senior director of investments for emerging company development. “Its efforts exemplify the significance of comprehending the problem, its impact on patients and the clinical environment for enhancing care and outcomes.” 

Read more about Deep Blue and its technology: Deep Blue expands innovative hernia technology to new surgical applications

Nancy Lamontagne, NCBiotech writer
scroll back to top of page